LY294002

Catalog No.S1105 Synonyms: SF 1101, NSC 697286

LY294002 Chemical Structure

Molecular Weight(MW): 307.34

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.

Size Price Stock Quantity  
In DMSO USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 770 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 70 Publications

13 Customer Reviews

  • Type I IFNs induce ISG expression in a serine phosphorylation-independent manner. Cells were treated with kinase inhibitors (SB203580, rottlerin, Ly294002, PD98059, and SP600125) before stimulation with IFN-a and IFN-b for 6 hours. Cell lysates were used in western blotting and probed for serine phosphorylation.The relative amounts of pSTAT1 S727 in (up-graph) were quantied and normalized to an untreated control (below-graph).

    Hepatology 2014 59(4), 1262-72. LY294002 purchased from Selleck.

    different signal-inhibitory profile by applying 120 nmol/L BGT226, 20 μmol/L LY294002, or 100 nmol/L rapamycin in FaDu cells.

    Clin Cancer Res 2011 17, 7116-7126. LY294002 purchased from Selleck.

  • Stimulation response of p37d-expressing cells. (c) Western blot of 5 min serum stimulated HEK-293 cells stably expressing p37d, p110d or control, with the presence of inhibitors as indicated at the top.

    Oncogene 2012 31, 3277–3286. LY294002 purchased from Selleck.

    PTEN transfection or inhibition of the PI3K-AKT and IGF-1R signaling pathways increases the trastuzumab sensitivity of NCI-N87/TR cells. After treating the cells with a PI3K inhibitor (LY294002), the expression of AKT and P-AKT proteins was assessed by Western blotting. Tubulin expression indicated equal loading. All gels run under the same experimental conditions and the experiments were repeated 3 times. The representative images were cropped and shown. Control: cells without any treatment.

    Sci Rep 2015 5, 11634. LY294002 purchased from Selleck.

  • SCC61 or Detroit 562 xenografted tumors respond to treatment by PI3K inhibitor, LY294002 alone, or in combination with gefitinib. % tumor growth is shown. By two-way ANOVA, the effect of treatment and time is considered significant;

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

    Inhibition of EGFR and PI3K/AKT pathway has additive effects in SCCHN cell lines with constitutively active PIK3CA mutations, while removing negative regulation of PI3K/AKT pathway increases resistance in sensitive SCCHN cell line. A, results from MTT assays on cells treated with PI3K inhibitor, LY294002, and gefitinib.

    Mol Oncol 2013 7, 359-68. LY294002 purchased from Selleck.

  • Immunofluorescence and flow cytometric analyses of the translocation of ABCG2 in MCF-7 FLV1000 cells before and after treatment with the PI3K inhibitor LY294002. Confocal microscopy of MCF-7 FLV1000 cells after a 16-h treatment with 2 uM or 4 uM of LY294002 was performed as described in Figure.

    Br J Pharmacol 2013 70(5), 1137-51. LY294002 purchased from Selleck.

    IGF1 increases apical fibronectin in late stage blastocysts. Representative confocal images of blastocysts stained for fibronectin (Green) and DAPI (Blue). Day 5 blastocysts were cultured in SS medium for 24 (A and B), 48 (C and D) or 72 h (E-H) in the absence (A, C and E) or presence (B, D and F) of 10 ng/ml IGF1 or in the presence of a PI3 Kinase inhibitor (5 uM LY294002 + 10 ng/ml IGF1) (G) or in the presence of 10 ng/ml IGF1, attached to a coverslip (H). Scale bars represent 20 mm. Red line indicates location of coverslip. Arrow indicates location of the inner cell mass (ICM). The following total number of blastocysts were analysed, from at least 3 experimental repeats in each treatment; 24 in the SS group (24 h), 21 in SS plus IGF1 (24 h), 26 in SS (48 h), 30 in SS plus IGF1 (48 h), 40 in SS (72 h), 59 in SS plus IGF1 (72 h), 13 in SS plus IGF1 + LY294002 (48 h) and 15 blastocysts were analysed that were attached to a coverslip (72 h).

    Hum Reprod 2015 30(2), 284-98. LY294002 purchased from Selleck.

  • Inhibition of PI3K, ERK and mTOR prevents the activation of S6K1 and S6 induced by suppression of PKD1 activity. A549 cells were incubated in the absence (-) or presence of either 5 uM Kb or 5 uM Kb and 20 uM LY294002 or 5 uM Kb and 10 uM BKM120 (as indicated) for 1 h prior to stimulation of cells with 50 nM PMA for 30 min and 1 h.

    Int J Biochem Cell Biol 2015 60, 34-42. LY294002 purchased from Selleck.

    Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

  • Comparative effects of wortmannin and LY294002 on ADRP and β -casein synthesis. Con fluent HC11 cells were treated according to the standard procedure in the absence or presence of 4 ng/ml EGF either with or without 100 nM wortmannin or 50μM LY294002. Cellular proteins were analyzed by SDS-PAGE and immunoblot successively probed with anti-ADRP, anti-β-casein, anti-β -actin antibodies and their respective HRP-conjugated secondary antibodies. ECL signals were quantified by densitometry and normalized to β-actin. Each experimental condition was performed in triplicate. Percentages of inhibition for both inhibitor and hormonal treatments are indicated in the text.

    Biochim Biophys Acta 2012 1823(5), 987-96. LY294002 purchased from Selleck.

    We treated all of drugs in T47D which has a PI3KCA H1044R mutation with the concentration shown below for 1 hour and performed western blot analysis using antibodies to phospho-AKT(SERINE 472), and total AKT.

     

     

    2010 Saraswati Sukumar of Johns Hopkins University School of Medicine. LY294002 purchased from Selleck.

  • T47Dcells were pretreated with 100 ng/ml EGF for 20 min and then treated with the indicated concentrations of LY294002 for 24 hours.

     

     

    2010 Dr. Zhang of Tianjin Medical University. LY294002 purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM in cell-free assays, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation.
Targets
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
0.5 μM 0.57 μM 0.97 μM
In vitro

LY294002 inactivates Akt/PKB, consequently inhibiting cell proliferation and inducing apoptosis. LY294002 demonstrates a remarkable growth-inhibitory and apoptosis-inducing effect in these colon cancer cell lines, with decreased expression of phosphorylated Akt (Ser473). [2]LY294002 induces marked nuclear pyknosis and diminished cytoplasmic volume in the tumor cells. Thus, LY294002 markedly inhibits ovarian cancer cell proliferation in vitro. LY294002 induces specific G1 arrest in cell growth, leading to almost complete inhibition of melanoma cell proliferation and partial inhibition of MG-63 (osteosarcoma cell line) proliferation. The effect of LY294002 on cell cycle progression may provide insights into a possible link between the PI3K activation pathway and cancer cell cycle regulation. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 cells NUf2VYxyS2WubDDpcpZie2mxbjDhd5NigQ>? MVeyOEBp NFTOPFRKdmirYnn0bY9vKG:oIHXwbZRp\WyrYXyg[5Jwf3SqIH\hZ5Rwei2rbnT1Z4VlKGOnbHygcYloemG2aX;uJI9nKGi3bXHuJG1FSS2PQj2yN|Eh[2WubIOgdJJmNWmwY4XiZZRm\CCob4KgNlQhcHK|IHL5JINmdGxiaX72ZZNqd25iYYPzZZktKEmFNUC9NE4{QCEQvF2u NUn6[ZBoOjJ6MESxNFg>
Sf21 cells NWXxO5J[TnWwY4Tpc44h[XO|YYm= MXnJcohq[mm2aX;uJI9nKG2xdYPlJJdqdGRidInw[UBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmNlEh[2WubIOgZ48u\XiycnXzd4lv\yCQLYTldo1qdmGuIFjpd{11[WepZXSgbJVu[W5icEi1ZUB2e2mwZzDMMYFteGijLYDoc5NxcGG2aXT5cIlvd3OrdH;sJJN2[nO2cnH0[UBjgSCWTFOgZoF{\WRicHjvd5Bpd3JiaX3h[4lv\yxiSVO1NF0xNjVizszN NEjUV3czOjV{ME[zNC=>
Sf21 cells NIXCVGRHfW6ldHnvckBie3OjeR?= MVzJcohq[mm2aX;uJI9nKG2xdYPlJJJm[2:vYnnuZY51KFCLM1vhcJBp[SCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMucW6oZXP0[YQhW2Z{MTDj[YxteyxiSVO1NF0xNjVizszNMi=> M3niR|E6PzR6Mk[5
Sf9 cells MUDGcJVwemW|Y3XueEBxd2yjcnn6ZZRqd25iYYPzZZk> MnHITY5pcWKrdHnvckBw\iCqdX3hckBRUTONYXzwbIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[XluIFnDOVA:OC53NTFOwG0v NHfWdFMzOTF{MU[zNS=>
THP1 cells NU\4cWU3TnWwY4Tpc44h[XO|YYm= NFjjUVdKdmirYnn0bY9vKG:oIGPDSlEucW6mdXPl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBVUFBzIHPlcIx{NCCLQ{WwQVEvODFizszNMi=> MmHWNVY4QDl5NEK=
human PC3 cells MWfGeY5kfGmxbjDhd5NigQ>? MoLxN|AhdWmw MYDJcohq[mm2aX;uJI9nKFCLM1ugbY4hcHWvYX6gVGM{KGOnbHzzJIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIFHLWEBxcG:|cHjvdplt[XSrb36gZZQhe2W{aX7lJFQ4OyCjZoTldkA{OCCvaX7zJIJ6KEWOSWPBMEBKSzVyPUGuN:69VS5? NG\zWXEzOzRzMECwOS=>
HeLa (human carcinoma) cells. M3XCRmZ2dmO2aX;uJIF{e2G7 M4\KcmlvKH[rdILvJIlvcGmkaYTpc44hd2ZiRF7BMYRmeGWwZHXueEBxem:2ZXnuJItqdmG|ZTjEUmEuWEtrIH\yc40hUGWOYTCobJVu[W5iY3HyZ4lvd22jKTDj[YxteyxiSVO1NF0yNjRizszNMi=> MVyxOVY2QDh5MB?=
THP1 cells NI\GNnRHfW6ldHnvckBie3OjeR?= MYTJcohq[mm2aX;uJI9nKE2FUEGtbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDUTHAyKGOnbHzzMEBKSzVyPUGuOlUh|ryPLh?= Mnv4NVY4QDl5NEK=
HeLa cells MV;GeY5kfGmxbjDhd5NigQ>? MnXlTY5pcWKrdHnvckBw\iCvVF;SJJBzd3SnaX6gbZNwdGG2ZXSg[pJwdSCKZVzhJINmdGy|LDDJR|UxRTJwNTFOwG0v M1\NclE2PjV6OEew
human MCF7 cells MnjPR5l1d3SxeHnjxsBie3OjeR?= M{DVdGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMhcW5icILld4Vv[2Vib3[gNlAh|ryPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0zNjZ|IN88UU4> MYKxPFY6OTh7NB?=
HeLa cells M3XNc2Z2dmO2aX;uJIF{e2G7 MW\Jcohq[mm2aX;uJI9nKEG[LUe1NFMh[mmwZHnu[{B1dyC{ZXPvcYJqdmGwdDDQcIs{KGW6cILld5Nm\CCrbjDI[WxiKGOnbHzzJIJ6KFenc4Tldo4h[myxdDygTWM2RTNizszNMi=> MnnoNVcyOzV{NEi=
human MCF7 cells M3TOeWN6fG:2b4jpZ:Kh[XO|YYm= NHLmXZJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGmwIIDy[ZNmdmOnIH;mJFExKHWPIHPocI9zd3G3aX7lJIJ6KFOUQjDhd5NigSxiR1m1NF0{NjB6IN88UU4> NVL4UlJHOTh4OUG4PVQ>
human MCF7 cells M1nBPGN6fG:2b4jpZ:Kh[XO|YYm= NGHqVYlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGK7IGPSRkBie3OjeTygS2k:Oy5zNjFOwG0v MV:xPFY6OTh7NB?=
human MDA-MB-231 cells MXvDfZRwfG:6aXRCpIF{e2G7 NV7oW|MzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BqdiCycnXz[Y5k\SCxZjCyNEDPxE1iY3jsc5JweXWrbnWgZpkhW1KEIHHzd4F6NCCJSU2zMlMzKM7:TT6= MYmxPFY6OTh7NB?=
human MDA-MB-231 cells MmTBR5l1d3SxeHnjxsBie3OjeR?= MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD12LkO1JO69VS5? M2i2RVE5PjlzOEm0
human MDA-MB-468 cells MVrDfZRwfG:6aXRCpIF{e2G7 NGnZOWZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtOFY5KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIEKwJJVOKGOqbH;yc5F2cW6nIHL5JHNTSiCjc4Phfg+9lCCLQ{WwQVQvPzZizszNMi=> Ml75NVg3QTF6OUS=
human HCT116 cells NUHIbmdDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NFTtOYM1QCCq MULHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJGgyODR5UjDteZRidnRiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF02NjNizszN M17V[|IzOjF{N{Kx
human HCT116 cells M1rHUWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MoS3OFghcA>? MnvtS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OU45KM7:TT6= NX3qNpp[OjJ{MUK3NlE>
HeLa cells NGXqNG5DcW6maX7nJIFn\mmwaYT5JIF{e2G7 NH\yO3ZDcW6maX7nJIFn\mmwaYT5JIZweiCSSUOtb4lv[XOnIHnzc4xifGWmIH\yc40hUGWOYTDj[YxteyxiS3m9OkDPxE1? Mly2NVU3PTh6N{C=
human HCT116 cells MlPnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MV60PEBp MVzHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIR3QyOTZiY3XscJMhd3[ncnX4dJJme3OrbnegVGk{U2GucHjhJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;Nj63JO69VS5? NGfjNHIzOjJzMkeyNS=>
MDA-MB-231 cells MWLDfZRwfG:6aXRCpIF{e2G7 NWe4epVYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVI{OSClZXzsd{BjgSCVUlKgZZN{[XluIFfJOVA:Pi55MTFOwG0v M4rqXlE5PjlzOEm0
Sf9 cells M2rkeWZ2dmO2aX;uJIF{e2G7 Ml\iTY5pcWKrdHnvckBw\iCFS{Kg[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF03NjlizszNMi=> MmfINVg{OjF5MU[=
human U87MG cells Mo\tSpVv[3Srb36gZZN{[Xl? NEHpUZhKdmirYnn0bY9vKG:oIFfTT|Mu[mW2YTDpckBpfW2jbjDVPFdOTyClZXzsd{BjgSCHTFnTRUwhUUN3ME24MlEh|ryPLh?= NGmzfGIyQDN2NU[wPS=>
human MDA-MB-468 cells M{PRW2N6fG:2b4jpZ:Kh[XO|YYm= MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvNE[4JINmdGy|IHnuJJBz\XOnbnPlJI9nKDFyIIXNJINpdG:{b4H1bY5mKGK7IGPSRkBie3OjeTygS2k2OD16LkKg{txONg>? MlnFNVg3QTF6OUS=
human A375 cells Ml70VJJwdGmoZYLheIlwdiCjc4PhfS=> NGjpWYM1PiCq NUTBWlJ4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IES2JIhzeyxiSVO1NF05NjRizszNMi=> NVPSS49{OTdyNEmyOFg>
human A375 cells MVXQdo9tcW[ncnH0bY9vKGG|c3H5 M3fKcWlvcGmkaYTpc44hd2Zic3XyeY0ucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJIh2dWGwIFGzO|Uh[2WubIOsJGlEPTB;OD60JO69VS5? NFex[I0yPzZyMUezPS=>
human HL60 cells NWD5O|VYS3m2b4TvfIlkyqCjc4PhfS=> MXK3NkBp MWrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OT65OEDPxE1w NH;DVFAzOjR6MEi1NS=>
mouse Raw264 macrophage Mof2SpVv[3Srb36gZZN{[Xl? NEnqV25KdmirYnn0bY9vKG:oIFO1ZU1u\WSrYYTl[EBRU0JxQXv0JJBpd3OyaH;yfYxifGmxbjDpckBud3W|ZTDSZZczPjRibXHjdo9xcGGpZTygTWM2OD1zMDFOwG0v MVSxOlc5QTd2Mh?=
Sf9 cells MUTGeY5kfGmxbjDhd5NigQ>? MYfJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiYn;2bY5mKFCLM1ug[ZhxemW|c3XkJIlvKFOoOTDj[YxteyxiSVO1NF0yOCEQvF2u M3Hk[lExQTl6M{Wx
human MDA-MB-468 cells M3WwUGN6fG:2b4jpZ:Kh[XO|YYm= MmHYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUS2PEBk\WyuczDifUBUWkJiYYPzZZktKEmFNUC9NVAvPCEQvF2u MWqxPFY6OTh7NB?=
human PC3 cell Mnu0VJJwdGmoZYLheIlwdiCjc4PhfS=> M2XzZVczKGh? MWXJcohq[mm2aX;uJI9nKGi3bXHuJHBEOyClZXzsJJBzd2yrZnXyZZRqd25iYX\0[ZIhPzJiaILzJIJ6KHOyZXP0do9xcG:2b33leJJq[yCjbnHsfZNqeyxiSVO1NF0yOi5zIN88UU4> NGjZWIQzOzRzMECwOS=>
human HL60 cells NVfOPZFYWHKxbHnm[ZJifGmxbjDhd5NigQ>? NIP0Tmc4OiCq M{nBbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHid49z[mGwY3WgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OD1zOD60N{DPxE1w MlLzNlU3QTN5OEe=
human BT474 cell MkT4VJJwdGmoZYLheIlwdiCjc4PhfS=> NIfs[Hg4OiCq MmPzTY5pcWKrdHnvckBw\iCqdX3hckBDXDR5NDDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IIPw[YN1em:yaH;0c41mfHKrYzDhcoFtgXOrc,-8kEBKSzVyPUKwMlch|ryPLh?= NGjLcmkzOzRzMECwOS=>
THP1 cells M3q5UGZ2dmO2aX;uJIF{e2G7 NEfpV2tKdmirYnn0bY9vKG:oIF3DVFEucW6mdXPl[EBkcGWvb4ThfIl{KG:oIGTIVFEh[2WubIOsJGlEPTB;M{eg{txONg>? MnPBNVY4QDl5NEK=
human 184B5 cells M3znPWN6fG:2b4jpZ:Kh[XO|YYm= MmK4R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gNVg1SjViY3XscJMh[nliU2LCJIF{e2G7LDDHTVUxRTN7LkO3JO69VS5? MnvrNVg3QTF6OUS=
human KB cells M1W0PWN6fG:2b4jpZ:Kh[XO|YYm= M1HuRlczKGh? NUnEUYlOS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0JiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME20OE44PiEQvF2u NVKxU2x6OjF7NEWyOVA>
mouse RAW264.7 cells M1T2RWZ2dmO2aX;uJIF{e2G7 MoD0NlUh|ryP NYTPdnB[OjBiaB?= NH;VTHJKdmirYnn0bY9vKG:oIGDJN2swSUuWIHnuJI1wfXOnIGLBW|I3PC55IHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRiaV7PV{Bxem:2ZXnuJIV5eHKnc4Ppc44h[XRiMkWg{txOKGGodHXyJFIxKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN? Mnf4NlQzQTl4MU[=
human A2780 cells M1zOWWFxd3C2b4Ppd{Bie3OjeR?= NEfzTJgzKM7:TR?= NX7lSHZVOTJiaB?= NXOxW5dTUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBkcXOybHH0bY4uemW|aYP0ZY51KGi3bXHuJGEzPzhyIHPlcIx{KGG|c3Xzd4VlKGG|IHTlZ5Jm[XOnIHnuJJBpd3OyaH;yfYxifGWmIFHreEBt\X[nbDDheEAzKHWPIHHmeIVzKDF{IHjyd{BjgSCrbX31co9jdG:2IHHuZYx6e2m|Lh?= MkLXNVc3QDRyMUi=
human SW480 cells MWHGeY5kfGmxbjDhd5NigQ>? MWqyNEDPxE1? Mk\5NlQhcA>? MlrGSIVkemWjc3WgbY4he3W{dnn2bY4h\XiycnXzd4lwdiCrbjDoeY1idiCVV{S4NEBk\WyuczDheEAzOCC3TTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdDDhcoFtgXOrcx?= MWexO|Q4Ojl4Mh?=
mouse mast cells MmnnSpVv[3Srb36gZZN{[Xl? M1\SN|IxKM7:TR?= Ml74TY5pcWKrdHnvckBw\iCVQ1[tbY5lfWOnZDDQT2IwSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDtc5V{\SCvYYP0JINmdGy|IHH0JFIxKM7:TR?= M3;QZVE3Pzh7N{Sy
human BJ cells NVvvfXE2TnWwY4Tpc44h[XO|YYm= NUfLU21IOjVizszN NHXsVGUzKGh? NW\5eIhEUW6qaXLpeIlwdiCxZjDQTVNMKHOrZ37hcIlv\yCrbjDQSGdHNXO2aX31cIF1\WRic3XyeY0he3Sjco\l[EBpfW2jbjDCTkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIIDsZZNucWRiRVfGVE9RUCCmb33hbY4hd2ZiQXv0JIF{e2W|c3XkJIF{KHO3cIDy[ZN{cW:wIH;mJHBJNUWJRmCgdoVlcXO2cnnieZRqd25idH:gdIxie22jIH3lcYJz[W6nIHH0JFI2KHWPIITy[YF1\WRiMjDodpMh[mWob4LlJHBFT0ZiY3jhcIxmdmenIHL5JINwdm[xY3HsJI1q[3Kxc3PvdJk> NYD6cHNnOTZ5NkewPFU>
human IGROV1 cells NYPFPGh3TnWwY4Tpc44h[XO|YYm= NFu4bZIzPC92ODDo NVnJdGRKUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiQVvUJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= NILST3ozOTJzNkG1NS=>
human IGROV1 cells M1HtdmZ2dmO2aX;uJIF{e2G7 Ml7tNlQwPDhiaB?= NWSyeolLUW6qaXLpeIlwdiCxZjDQTVNMN0GtdDDpckBpfW2jbjDJS3JQXjFiY3XscJMh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gZ5lkdGmwIFSxJIxmfmWuIHH0JFEhfG9iNTD0bY1meyCLQ{WwJIFnfGW{IEK0JJRwKDR6IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MmPiNlEzOTZzNUG=
rat RBL2H3 cells MXPGeY5kfGmxbjDhd5NigQ>? MWfJcohq[mm2aX;uJI9nKEF{M{G4O{1qdmS3Y3XkJIRm\3KjboXsZZRqd25iaX6gdoF1KFKETELIN{Bk\Wyucx?= Mo\WNVg{Ojh5MU[=
human BJ cells NH3iUmJHfW6ldHnvckBie3OjeR?= MY[yOUDPxE1? NHTNZpQzKGh? MVnBZ5RqfmG2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iYYSgWIhzOzB6IHnuJHBFT0Zvc4TpcZVt[XSnZDDz[ZJ2dSC|dHHyeoVlKGi3bXHuJGJLKGOnbHzzJIF1KDJ3IIXNJJRz\WG2ZXSgNkBpenNiYnXmc5JmKFCGR1[gZ4hidGynbnflJIJ6KGmvbYXuc4Jtd3S2aX7n M1XTSlE3PzZ5MEi1
human HCT116 cells NWWwPI1jTnWwY4Tpc44h[XO|YYm= NETTSncyOCEQvF2= NGeyT5kyOCCvaX6= NHXRfIJKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMhfXOrbnegX|MzWF2DVGCgZZQhOTBidV2gZYZ1\XJiMUCgcYlvew>? NV3NWXBtOjJ{MUK3NlE>
human HCT116 cells M2\DXGZ2dmO2aX;uJIF{e2G7 MUGxNEDPxE1? NXLadpB{OTBibXnu NUTwSolyUW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgTFExPDeUIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgeZNqdmdiW{OyVH1CXFBiYYSgNVAhfU1iYX\0[ZIhOTBibXnudy=> NUe0[HFXOjJ{MUK3NlE>
human HCT116 cells NX3pSIFjTnWwY4Tpc44h[XO|YYm= NX3VWZFROTBizszN NGLTOoJKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDpckBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCc3RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBifCBzMDD1UUBjgSCrbX31co9jdG:2IHHuZYx6e2m| MWeyNlIyOjd{MR?=
human HCT116 cells MX3GeY5kfGmxbjDhd5NigQ>? NXvpTWNNOTBizszN NX;PZ|M6UW6qaXLpeIlwdiCxZjDQTVNM[WyyaHGgTFExPDeUIH31eIFvfCCrbjDoeY1idiCKQ2SxNVYh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{ M4rx[FIzOjF{N{Kx
human PC3 cells NGPRflRHfW6ldHnvckBie3OjeR?= M3PCVVUxKM7:TR?= MXS4JIg> M{DoVWlv\HWldHnvckBw\iCyMkGgdJJwfGWrbjDlfJBz\XO|aX;uJIlvKGi3bXHuJHBEOyClZXzsd{BifCB3MDD1UUBqdmO3YnH0[YQh\m:{IEigbJJ{KGK7IGfld5Rmem5iYnzveJRqdmdicnXsZZRqfmVidH:geY51emWjdHXkJINwdnS{b3y= M3v3dFIzQTl6NEey
human LNCAP cells MUHGeY5kfGmxbjDhd5NigQ>? NYi1[nZGOC5zLUOwJO69VQ>? MY[zNEBucW5? MlzyTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIHnuJIh2dWGwIFzOR2FRKGOnbHzzJIF1KDBwMTD0c{A{OCC3TTDh[pRmeiB|MDDtbY5{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> MWeyNlg{OjNzNh?=
human LNCAP cells MoPESpVv[3Srb36gZZN{[Xl? NXrBe4liOC5zLUOwJO69VQ>? NIfoWZEzPCCq MnfoSI94dnKnZ4XsZZRqd25ib3[gd5Vzfmm4aX6g[ZhxemW|c3nvckBqdiCqdX3hckBNVkODUDDj[YxteyCjdDCwMlEhfG9iM{CgeW0h[W[2ZYKgNlQhcHK|IHL5JHdme3Sncn6gZoxwfCCjbnHsfZNqew>? NWfpTWsyOjJ6M{KzNVY>
HUVEC NYj0NZpvTnWwY4Tpc44h[XO|YYm= M2PPXFExNTJ3IN88US=> NWXxe2d7OTZiaB?= MlTFTY5pcWKrdHnvckBw\iCWTl\hcJBp[S2|dHnteYxifGWmIFnDRW0uOSCvUl7BJIV5eHKnc4Ppc44hcW5iSGXWSWMh[XRiMUCgeI8hOjVidV2gdJJmfHKnYYTl[EBnd3JiMU[gbJJ{KGKnZn;y[UBVVk[jbIDoZUBkcGGubHXu[4UhdWWjc4Xy[YQh[W[2ZYKgOkBpenNiYomgVnQuWEOUIHHuZYx6e2m| NXPicHdoOjJyMk[0NVA>
HUVEC NVvDd3d{TnWwY4Tpc44h[XO|YYm= MUWxNE0zPSEQvF2= M2rIN|MxKG2rbh?= NE\BfnRKdmirYnn0bY9vKG:oIGTOSoFteGijLYP0bY12dGG2ZXSgbJVu[W5iSVPBUU0yKHC{b33veIVzKGGldHn2bZR6KGW6cILld5Nm\CCrbjDIWXZGSyCjc4Pld5Nm\CCjczDi[ZRiNWejbHHjeI9{cWSjc3WgZYN1cX[rdImgZZQhOTBidH:gNlUhfU1icILleJJm[XSnZDDmc5IhOzBibXnud{Bj\W[xcnWgWG5H[WyyaHGgZ4hidGynbnflJI1m[XO3cnXkJIFnfGW{IEWgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfS=> NHHGPVgzOjB{NkSxNC=>
human H1299 cells MlXvSpVv[3Srb36gZZN{[Xl? MkXDNE4yNTNyIN88US=> NWTXU2dtOjRiaB?= MXnEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=> M3K0dlIzPjJ{ME[5
human H1299 cells MVfGeY5kfGmxbjDhd5NigQ>? Mly4NE4yNTNyIN88US=> NUDD[oxLOjRiaB?= MWfEc5dvKHKnZ4XsZZRqd25ib3[gZ2lCWDJiZYjwdoV{e2mxbjDpckBpfW2jbjDINVI6QSClZXzsd{BifCByLkGgeI8hOzBidV2gZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjCxNFAhfWdxbXygWHJCUUxiYX7kJHBKO0tiaX7obYJqfG:{IFzZNlk1ODB{ MUmyNlYzOjB4OR?=
human H1299 cells MV3GeY5kfGmxbjDhd5NigQ>? M{XwNFAvOS1|MDFOwG0> M2HrflI1KGh? MXPJcoR2[3Srb36gc4YhTFJ3IHX4dJJme3Orb36gbY4hcHWvYX6gTFEzQTliY3XscJMh[XRiMD6xJJRwKDNyIIXNJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> M{DQblIzPjJ{ME[5
human H1299 cells MWTGeY5kfGmxbjDhd5NigQ>? M3X3dlAvOS1|MDFOwG0> NW\BNZRiOjRiaB?= MmnwTY5lfWO2aX;uJI9nKEqQSz3t[YRq[XSnZDDDTG9RKGW6cILld5Nqd25iaX6gbJVu[W5iSEGyPVkh[2WubIOgZZQhOC5zIITvJFMxKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MkPzNlI3OjJyNkm=
HEK293 cells MYXGeY5kfGmxbjDhd5NigQ>? MlvwNU42KGh? NIOxUmpFcXOybHHj[Y1mdnRib3[gX|NJZUyVRDDmdo9uKGi3bXHuJFVJXDZicnXj[ZB1d3JiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyNjViaILzJIJ6KGyrcYXp[EB{[2mwdHnscIF1cW:wIHPveY51cW6p NHrnRWMzOjV|N{G1Ny=>
human U251HRE cells NXK5fGV3TnWwY4Tpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi7cH;4bYEucW6mdXPl[EBJUUZzIHHjeIl3[XSrb36gbY4hcHWvYX6gWVI2OUiURTDj[YxteyCkeTDj[YxtKGKjc3XkJJJmeG:{dHXyJIdmdmViYYPzZZk> NXPGNnFSOTh3MEG2NFE>
human HCT116 cells NYjodXZDTnWwY4Tpc44h[XO|YYm= M13pWlExKM7:TR?= NFfrd5lKdmirYnn0bY9vKG:oIFHreEBmgHC{ZYPzbY9vKGmwIHj1cYFvKEiFVEGxOkBk\WyuczDheEAyOCC3TTDifUBqdW23bn;icI91KGGwYXz5d4l{ NWHRXlZwOjJ{MUK3NlE>
Sf9 cells NYTSWmVR\my3b4Lld4NmdnRicH;sZZJqgmG2aX;uJIF{e2G7 Ml7lTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDifUBndHWxcnXzZ4VvfCCyb3zhdol7[XSrb36gZZN{[Xl? NX;KdGRiOjFzMkG2N|E>
human HCT116 cells MYnQdo9tcW[ncnH0bY9vKGG|c3H5 Ml7IO|IhcA>? NX7EN2ZbSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBi[nOxcnLhcoNmKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVEvQDJizszNMi=> NXv1RXZUOjV4OUO3PFc>
human HCT116 cells NWXXXnluS3m2b4TvfIlkyqCjc4PhfS=> MX:3NkBp Mk\aR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OVYvODFizszNMi=> MYKyNVk1PTJ3MB?=
human PC3 cells MoTFR5l1d3SxeHnjxsBie3OjeR?= NGroUlg4OiCq NYHXN4g5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUC9OlEvOzVizszNMi=> MVWyNlQ5ODh3MR?=
human HuH7 cells M{fLSnBzd2yrZnXyZZRqd25iYYPzZZk> NWXCTWZ{PzJiaB?= NWPRSlE{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIeWg4KGOnbHzzJIF{e2W|c3XkJIF{KGmwaHnibZRqd25ib3[gZYJ{d3KkYX7j[UBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPU[3MlE5KM7:TT6= NIS2Z4czPTZ7M{e4Oy=>
human A549 cells NHfG[2lRem:uaX\ldoF1cW:wIHHzd4F6 MoPKO|IhcA>? NHSzc2NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhZpNwemKjbnPlJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;OEKuN|Ih|ryPLh?= NXPY[|lFOjV4OUO3PFc>
human A549 cells NFTQR4FEgXSxdH;4bYPDqGG|c3H5 NV7ocI1oPzJiaB?= NV64d2xpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6 MYOyNlQ5ODh3MR?=
human PC3 cells NHnJZ2JRem:uaX\ldoF1cW:wIHHzd4F6 NI\IdGEzPSEQvF2= M3r0T|EzOCCq MmXqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYYSgNlUhfU1iYX\0[ZIhOTJyIHjyd{BjgSCPVGSgZZN{[XlicnXsZZRqfmVidH:gSG1UVw>? M1PQTVE3PjhyMUW5
human H460 cells M4HTXWZ2dmO2aX;uJIF{e2G7 MnjzN|Ah|ryP NXXycXJVUW6qaXLpeIlwdiCxZjDQTVNMKGmwIHj1cYFvKEh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgRYt1KHCqb4PwbI9zgWyjdHnvckBifCCVZYKgOFc{KHWyIITvJFMxKHWP NU\rclA5OTh3MEG2NFE>
human IGROV1 cells MXvGeY5kfGmxbjDhd5NigQ>? MnTMNlQhcA>? NWLlfG1HS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEAyKG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= M4PRSVIyOjF4MUWx
human IGROV1 cells NUmzd4NITnWwY4Tpc44h[XO|YYm= NGW3c5QzPCCq NWPtZ2lxS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hUUeUT2[xJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNUBxcGG|ZTDheEA2KG[xbHSgTWM2OCCjZoTldkAzPCCqcoOgZpkh\myxdzDjfZRwdWW2com= NXTYR4t5OjF{MU[xOVE>
human H4 cells MmTSSpVv[3Srb36gZZN{[Xl? M3fpVVIhcA>? NXn6ZoVDTGWlcnXhd4UhcW5iRmnWSU1TTlBtII\ld4lkdGViaX70[Y5{cXS7IIDldkBk\WyuIHnuJIh2dWGwIFi0JINmdGy|IHHmeIVzKDJiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> NHrsRo0yQDB{NEW4OC=>
human MGC803 cells NXzSTpJYTnWwY4Tpc44h[XO|YYm= NGrJ[YczPSEQvF2= MlTuOFghcA>? NW\ze2VrS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUeFOECzJINmdGy|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNk9OKHCqYYPlJIF1KDJ3IIXNJIFnfGW{IES4JIhzeyC3c3nu[{Bxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nJIFnfGW{IES4JIhzeyCkeTDmcI94KGO7dH;t[ZRmeiC{ZXzheIl3\SC2bzDjc451em:u NVP0TXY3OjRzMUm4Olk>

... Click to View More Cell Line Experimental Data

In vivo LY294002 also results in suppression of tumor growth and induction of apoptosis, especially in the LoVo tumors, and therefore shows remarkable effectiveness in the mouse peritonitis carcinomatosa model. [2] LY294002 significantly inhibits growth and ascites formation of ovarian carcinoma. [3]

Protocol

Kinase Assay:[4]
+ Expand

kinase assays:

PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1 μM ATP. The kinase reaction is carried out for 1 hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10 μM ATP.
Cell Research:[2]
+ Expand
  • Cell lines: Colon cancer cell lines DLD-1, LoVo, HCT15, and Colo205
  • Concentrations: 0–50 μM
  • Incubation Time: 0–48 hours
  • Method: 1.0×105 cells (100 μL volume/well) are inoculated into 96-well microtiter plates. LY294002 is added to triplicate wells and cultured at 37oC for 0–48 hours. After treatment, 10 μL of Premix WST-1 are added to each microculture well, and the plates are incubated for 60 minutes at 37oC, after which absorbance at 450 nm is measured with a microplate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Two groups of athymic nude mice (5–7 weeks) are inoculated i.p. with OVCAR-3 cells
  • Formulation: Dissolved in DMSO plus 0.25 ml of PBS
  • Dosages: 0–100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 36 mg/mL (117.13 mM)
Ethanol 21 mg/mL (68.32 mM)
Water Insoluble
In vivo Add solvents individually and in order:
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 307.34
Formula

C19H17NO3

CAS No. 154447-36-6
Storage powder
in solvent
Synonyms SF 1101, NSC 697286

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy LY294002 | LY294002 supplier | purchase LY294002 | LY294002 cost | LY294002 manufacturer | order LY294002 | LY294002 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID